Dyrnamix patented biomarker distinguishes patients likely to benefit from CRT
Dyrnamix has identified exRNA based non-invasive biomarker for predicting patient response to cardiac resynchronization therapy (CRT) that is more accurate than currently established methods.
Establish treatment for patients with CHF
Improves morbidity and mortality
$30,000 per procedure
$8.8 bn global market
Why: 30% of patients don't respond
Response linked to positive LV remodeling
Estimated cost in the EU alone of >$7 bn due to non-responders
What's Next: Mir-30d
Predicts positive LV remodeling
Predicts positive response to CRT
Ability to distinguish which patients most likely to benefit
Integrating genomic technology and bioinformatics
The Dyrnamix team employs sophisticated plasma ex-RNA extraction/identification techniques married with sophisticated genomics and big data analytics to develop an advanced platform for extracellular RNA identification, analysis and discovery of non-invasive biomarkers in cardiovascular disease.
Dyrnamix Discovery Engine
Extracellular RNA as a new clinical target.
The quantity of cell free extracellular RNA (ex-RNA) in the bloodstream of patients reflect the dynamic state of disease pathology and could be used to risk stratify patients by their current condition. Unlike many established biomarkers, ex-RNAs are implicated in disease pathogenesis and may serve as functional biomarkers to risk stratify patients, diagnostics to guide therapy or therapeutic targets to modify disease outcome.